Marksans Pharma is currently trading at RS. 217.40, up by 10.40 points or 5.02% from its previous closing of RS. 207.00 on the BSE.

The stock opened at RS. 211.45 and recorded a high of RS. 219.35 and a low of RS. 207.65. So far, 1,08,245 shares have been traded on the counter.

A BSE group 'A' stock with a face value of RS. 1, Marksans Pharma reached a 52-week high of RS. 358.50 on December 2, 2024, and a 52-week low of RS. 130.15 on June 4, 2024. In the past week, the stock's high and low were RS. 219.35 and RS. 190.05, respectively. The company’s current market capitalization stands at RS. 9885.77 crore.

The company's shareholding pattern includes 43.87% held by promoters, 26.26% by institutions, and 29.87% by non-institutions.

In a significant development, Marksans Pharma has received approval from the Australian Therapeutic Goods Administration (TGA) for its manufacturing facility at Plot A-1, Phase 1-A, Verna Industrial Estate, Goa. This approval allows the company to manufacture pharmaceutical formulations in solid dosage forms, including tablets and hard capsules, for the Australian market. The products will be produced in Goa and distributed in Australia through its subsidiary, Nova Pharmaceuticals Australasia.

Marksans Pharma specializes in research, manufacturing, and marketing of generic pharmaceutical formulations in global markets.